A5056546221- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Phagocytosis and Immune Regulation
- Cytokine Signaling Pathways and Interactions
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatitis C virus research
- Cancer Mechanisms and Therapy
- Liver Disease and Transplantation
- Apelin-related biomedical research
- Ferroptosis and cancer prognosis
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Respiratory Support and Mechanisms
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Respiratory and Cough-Related Research
- Intensive Care Unit Cognitive Disorders
- Endoplasmic Reticulum Stress and Disease
- Asthma and respiratory diseases
- Family and Patient Care in Intensive Care Units
- Oral Health Pathology and Treatment
- Cancer, Hypoxia, and Metabolism
- Surface Roughness and Optical Measurements
- Vascular Anomalies and Treatments
Chang Gung Memorial Hospital
2014-2024
Chang Gung University
2015-2024
Taipei Veterans General Hospital
1993-2024
National Taiwan University of Science and Technology
2023
Linkou Chang Gung Memorial Hospital
2015-2023
Fu Jen Catholic University
2018-2023
University of Taipei
2015
Sun Yat-sen University
2013
Third Affiliated Hospital of Sun Yat-sen University
2013
National Yang Ming Chiao Tung University
2003
Tumor recurrence in hepatocellular carcinoma (HCC) patients after radiofrequency ablation (RFA) remains common; some studies have reported that insufficient ablative margin RFA might contribute to HCC recurrence. The aim of this study was investigate whether safety margins determined by early computed tomography (CT) predicts RFA. This retrospective recruited with a single lesion our department between May 2013 and March 2014. Early follow-up CT performed within 7 days An adequate assessed...
Atezolizumab plus bevacizumab (atezo-bev) has been recommended for advanced hepatocellular carcinoma (HCC). High-dose external beam radiotherapy (RT) is recognized its excellent local tumor control. The efficacy and safety of concurrent atezo-bev with RT highly HCC minimally explored.
<b><i>Aim: </i></b>The aim of the study was to investigate impact early response (ER) hepatic arterial infusion chemotherapy (HAIC) on outcomes patients with advanced hepatocellular carcinoma (HCC) complicated major portal vein tumor thrombosis (PVTT). <b><i>Methods: </i></b>Thirty-nine receiving HAIC low-dose cisplatin, 5-fluorouracil (5FU), and leucovorin were enrolled. One course consisted 5 days treatment 2 rest per week for 4 consecutive...
Accumulating evidence suggests that human hepatocellular carcinoma (HCC) can be derived from cancer stem cells (CSCs), which contribute to tumor initiation, metastasis, chemoresistance, and recurrence. A great variety of HCC CSCs resulting in diverse clinical manifestations have been reported. However, how CSC diversity is regulated generated remains unclear. Here we report the miR‐200b–ZEB1 circuit closely involved with induction maintenance a group CSCs. We found miR‐200b downregulation...
Previously, a pilot genome-wide association study has identified candidate single nucleotide polymorphism predictors for the therapeutic response of 5-fluorouracil, mitoxantrone and cisplatin (FMP) combination chemotherapy in advanced hepatocellular carcinoma (HCC). Here, we conducted prospective confirmatory to examine predictive value rs9679162 (located on GALNT14 gene) responses using split-dose FMP protocol. One hundred seven HCC patients receiving therapy were enrolled. All Barcelona...
The combination of anti-angiogenic therapy and immune checkpoint inhibitors has revolutionized the management unresectable hepatocellular carcinoma (uHCC). While an early-phase study demonstrated promising outcomes for lenvatinib plus pembrolizumab (L+P) in treating uHCC, LEAP-002 trial did not meet its primary endpoint. However, comparative efficacy between L+P atezolizumab bevacizumab (A+B) as first-line treatment remains a topic uncertainty. This aimed to assess effectiveness safety...
Abstract Background The aim of this study was to evaluate the impact interval between diagnosis and treatment using radiofrequency (RF) ablation on survival patients with HCC detected through a surveillance program. Methods Between January 2004 July 2007, 121 cirrhotic 157 tumours program underwent RF ablation. A delay in defined as >5 weeks. mean length follow‐up 25 months (range 8–55 months). Cumulative analysed Kaplan–Meier method. Cox regression models were used identify factors...
Abstract Background A soluble form of cytotoxic‐T‐lymphocyte‐antigen‐4 (sCTLA‐4) is a prognostic biomarker for several cancers but remains unclear in HCC patients. The aim study to evaluate the predictive role serum sCTLA‐4 levels tumor recurrence chronic hepatis C (CHC)‐HCC patients receiving radiofrequency ablation (RFA). Material and method prospective recruiting 88 CHC‐HCC was done between 2013 2019. Cox regression analysis used determine predictors early recurrence. All tests were...
Background: Smoking tobacco, drinking alcohol, and chewing betel quid are health-risk behaviors for several diseases, such as cancer, cardiovascular disease, diabetes, with severe impacts on health. However, health care providers often have limited time to assess clients' regarding smoking intervene, if needed.
Abstract Many intensive care unit patients who undergo endotracheal extubation experience failure and require reintubation. Because of the high mortality rate associated with reintubation, postextubation respiratory management is crucial, especially for high-risk populations. We conducted present study to compare effectiveness oxygen therapy administered using high-flow nasal cannulae (HFNC) noninvasive positive pressure ventilation (NIPPV) in preventing reintubation among receiving...
Dupilumab, an antibody that binds IL-4Rα and inhibits IL-4 IL-13 signals, has demonstrated efficacy in chronic rhinosinusitis with nasal polyps (CRSwNP) primarily characterized by type 2 inflammation. Current evidence suggests the rate of improvement olfactory dysfunction dupilumab exceeds polyp reduction, yet underlying mechanism remains undisclosed. We hypothesize may initially ameliorate sensorineural dysfunction.
A genome-wide association study (GWAS) had identified a single nucleotide polymorphism (SNP), GALNT14-rs9679162, capable of predicting chemotherapy responses in advanced hepatocellular carcinoma (HCC). Here, we revisited the GWAS database to search for necessary SNPs that could improve our outcome prediction.A cohort 116 HCC patients receiving split-dose composed 5-fluorouracil, mitoxantrone and cisplatin was enrolled. The GALNT14-rs9679162 together with four other leading candidate...
This study evaluated the outcomes of hepatocellular carcinoma (HCC) patients with small normal liver volume (NLV) treated proton beam therapy (PBT) and introduced estimated standard (eSLV) as a new constraint.HCC NLV < 800 cm3 no distant metastasis who received treatment in our center were included. The doses PBT mainly 72.6 Gray equivalents (GyE) 22 fractions 66 GyE 10 according to tumor locations. Urata equation was used calculate eSLV.Twenty-two between November 2015 December 2016. 1-year...